Cervical Cancer Treatment Market Is Seeing Explosive Growth by Future Industry Winners: Forecast, 2020-2023

 The cervix is the lower part of the uterus that connects to the vagina. Cervical cancer develops in the cells of the cervix. Strains of Human Papillomavirus (HPV), a sexually transmitted infection, play a role in causing most of the cervical cancers. The disease begins when healthy cells acquire mutation leading to the uncontrolled growth of cells. These cells form a tumor which invades the nearby tissues. Squamous cell carcinomas, adenocarcinomas, and adenosquamous carcinomas are three types of cervical cancers. Squamous cell carcinomas develop from cells in the exocervix while adenocarcinomas develop from gland cells. The cancer cells are said to have features of squamous cells under the microscope. Adenosquamous carcinomas feature both squamous cell carcinomas and adenocarcinomas. Cryosurgery, laser surgery, simple hysterectomy, radical hysterectomy, and trachelectomy are various treatment options for cervical cancer. Cystoscopy, proctoscopy, examination under anesthesia, and imaging studies such as Computed Tomography (CT), Magnetic Resonance Imaging (MRI), intravenous urography, and Positron Emission Tomography (PET scan) are used of the diagnosis of cervical cancer.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5834 

The cervical cancer treatment market is mainly driven by the increasing prevalence of cervical cancer and increasing awareness about cervical cancer among women. Furthermore, the increasing demand for early diagnosis and treatment of cervical cancer is also expected to fuel the growth of the market during the review period. However, the high cost of treatment also fuels the growth of the market. The World Health Organization (WHO) stated that cancer was the leading cause of the total number of deaths globally in 2015 and was responsible for 8.8 million deaths.

Global Cervical Cancer Treatment market is expected to grow at a CAGR of 6.5% during the forecast period.

Segments 

The global cervical cancer treatment market is segmented on the basis of type, treatment, and end-user.

On the basis of type, the market is segmented into squamous cell carcinomas, adenocarcinomas, and adenosquamous carcinomas.

On the basis of treatment, the market is segmented into surgery, radiation therapy, chemotherapy, targeted therapy, hormone therapy, and others.

Surgery is further segmented into cryosurgery, laser surgery, simple hysterectomy, radical hysterectomy, trachelectomy, and others.

Radiation Therapy is further segmented into external beam radiation and brachytherapy

Chemotherapy is further segmented into cisplatin, carboplatin, paclitaxel, doxorubicin, gemcitabine, bevacizumab, and others.

Targeted therapy is further segmented into bevacizumab and pazopanib.

Hormone therapy is further segmented into oestrogen, progesterone, progestogens, and testosterone.

On the basis of end-user, the market is segmented into cancer care centers, diagnostic centers, pharmacies, and others.

Regional Analysis of the Global Cervical Cancer Treatment Market                 

Globally, Americas is the largest market for cervical cancer treatment whose growth is attributed to technological advancements in the field of oncology, increasing prevalence of cervical cancer, and development of new imaging devices by key players in the market. In North America, the market is driven by the increasing awareness of causes and risk factors of cervical cancer and its treatment. In the U.S., the market is driven by the increasing importance of women healthcare and changing lifestyle of women. South America exhibits a steady growth in the cervical cancer treatment market.

In the European countries, the growth of the market is attributed to a number of healthcare institutions offering treatment of cancer and huge investments in research and development activities by the U.K. and Germany. In Germany, the market is mainly driven by an increase in the use of new technological devices for the diagnosis and treatment of cancer.

In Asia Pacific, the cervical cancer treatment market exhibits numerous growth opportunities due to rising awareness about cervical cancer and the increasing demand for cost-effective treatment solutions such as chemotherapy. Japan, China, and India are the largest contributors to the market growth where the market is driven by the increasing emphasis on cancer detection and treatment and the rising prevalence of cancer. Additionally, availability of skilled healthcare professionals in research also accelerates the growth of the market. The increasing government support of oncology research and women healthcare initiatives and the rapid growth of the healthcare imaging industry in India and China fuel the f=growth of the market in the regions.

In the Middle East, Saudi Arabia and the United Arab Emirates (U.A.E.) are the largest contributors to the market growth due to the focus on the development of new healthcare facilities catering to the needs of cancer patients and availability of technologically advanced diagnostic devices of management. In African countries, the increasing number of healthcare initiatives for women health and improvement in healthcare infrastructure are likely to boost the growth of the market.

Key Players in the Global Cervical Cancer Treatment Market   

Some of the key players in this market are Pfizer Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, ALLERGAN, Actavis Pharma Company, Eli Lilly and Company, Alnylam Pharmaceuticals, Inc, Hetero, Biocon, Novartis, Genentech USA, and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/cervical-cancer-treatment-market-5834 

Bioburden Testing Market Excessive Growth Opportunities Estimated to be Experienced 2020-2023

 Global Bioburden Testing Market is expected to grow significantly over the forecast period. It is estimated that the global bioburden testing market is expected to register a CAGR of Approx. 9.15% during the forecast period of 2018–2023 with an estimated market value of USD 455 million. Bioburden testing refers to an estimation of microbial load on a medical instrument, raw material, packaged goods among others. Bioburden testing is carried out to ascertain if the types and numbers of micro-organisms present are satisfactory or unsatisfactory when compared to predefined acceptance criteria.

Several factors such as increasing food safety concerns, rising medical spending, growing product recalls due to microbial contamination are expected to drive the growth of the market. The major players are involved in strategic collaborations and new product launches to strengthen their position in the market. For instance, in October 2018, SGS SA acquired IBR Inc., a non-clinical contract research organization (CRO). IBR Inc. focuses on integral services in biopharmaceutical analytics for the development of biologics, biosimilars and vaccines, and provides several filter testing and particle counting services. 

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/6716

However, high costs of microbial enumeration instruments and complex and time-consuming regulatory standards in some economies may hinder the market growth during the assessment period. Also, test reports and certificates tend to be different from one country to another which hampers international trade. Therefore, in December 2017, International Organization for Standardization (ISO) published a new edition of ISO/IEC 17025 standard. This standard is an international reference for laboratories carrying out calibration and testing activities around the world. ISO/IEC 17025 helps facilitate cooperation between laboratories and other bodies by generating wider acceptance of results between countries.

Segmentation:

The global bioburden testing market has been segmented into test type, product type, application and end-user.

The market, on the basis of type, has been segmented into aerobic count, anaerobic count, fungi count and spore count.

The market, on the basis of product type, has been segmented into consumables and instruments.

The market, by consumables, has been sub-segmented into reagents and kits, and others.

The market, by instruments, has been further segmented into polymerase chain reaction machine (PCR), microscopes, and others.

The market, by application, has been segmented into raw materials testing, medical devices testing, in-process material testing, sterilization validation testing, and equipment cleaning validation.

The market, by end-user, has been segmented into pharmaceutical and biotechnology companies, microbial testing laboratories, and others.

The market, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The bioburden testing market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European bioburden testing market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The bioburden testing market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The Bioburden Testing market in the Middle East & Africa has been segmented into the Middle East and Africa.

Key players:

Charles River, SGS SA, WuXi AppTec, Merck KGaA, NORTH AMERICAN SCIENCE ASSOCIATES INC., Becton, Dickinson, and Company, Nelson Laboratories, LLC, Pacific Biolabs, ATS Laboratories, Inc., and Dynatec Labs are some of the major players in the global bioburden testing market.

Geographically, the Americas is anticipated to dominate the global bioburden testing market owing to a well-developed healthcare infrastructure, and growing healthcare expenditure. Moreover, favourable reimbursement scenario in this region fuels the growth of the market.

Europe is expected to hold the second largest position in the global bioburden testing market. The market growth in this region is attributed to the availability of funds for research.

Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population, continuously developing economies, and increasing government funding for healthcare sector. Also, there is a strong presence of major players in this region which boosts the market growth.

On the other hand, the Middle East and Africa has the least share of the market. Majority of the market share of this region is expected to be held by the Middle East region due to the growing government initiatives for the healthcare sector.

Browse More Details of the Report @  https://www.marketresearchfuture.com/reports/bioburden-testing-market-6716

Global Hemiplegic Migraine Market to Witness Steady Growth through 2023

 Hemiplegic migraine, although a rare type of migraine its symptoms are almost same as other migraines.  Intense and throbbing pain, nausea, and sensitivity to light and sound are some of the symptoms caused by hemiplegic migraine. “Hemiplegia” means paralysis and people suffering from it literally feel temporary symptoms of paralysis such as temporary weakness, numbness and tingling, and paralysis on one side of the body which start before the headache.

Although the hemiplegic migraine is considered as a rare disorder affecting a small number of people, over the past few years, the prevalence of hemiplegic migraine has been increasing. Out of the two types of hemiplegic migraine, familial hemiplegic migraine (FHM) is a hereditary condition that affects at least two close relatives in the same family.  

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/6713

Whereas, the other type, sporadic hemiplegic migraine (SHM) can affect anyone even those who don’t have any family history of the condition. Factors such as changing lifestyle, environmental changes, pollutions, etc. are causes behind the occurrence of SHM. As a result, sporadic hemiplegic migraine is more prevalent than FHM.

However, there are a number of treatment methods available to treat both the types of hemiplegic migraines owing to the technological advancements that happened in the field of medical science in the recent years. Growing prevalence and the availability of treatments are the two key driving forces behind the market growth of hemiplegic migraines.

Considering all these factors, the global market of the hemiplegic migraine is expected to reach approximately 1008 MN USD by the end of 2023, growing at a CAGR of approximately 3.3% during the forecast period (2018-2023). In 2017, the market had valued at USD 830 Million.

Segments

The global hemiplegic migraine market has been segmented on the basis of type, treatment, preventive treatment, distribution channel, end-user, and region. By type, the market is segmented into familial hemiplegic migraine and sporadic hemiplegic migraine. By end-user, the market is segmented into hospitals & clinics, diagnostic centers, and others.

By treatment, the market is segmented into acute treatment, triptans, ergotamines, nsaids, antiemetics, narcotic analgesics, and others. By preventive treatment, the market is segmented into antidepressants, botox injections, and others. By distribution channel, the market is segmented into retail pharmacies, hospital pharmacies, online pharmacies, and others. By region, the market is segmented into the Americas, Europe, Asia Pacific, and the Middle East & Africa.

Regional analysis

The Americas accounts for the leading market due to the higher health care expenditures. The fastest uptake of new technologies in the growing healthcare sector is a major driving force driving the market. The presence of well-established market players is fuelling the market.

The market in the European region stands at the second position in terms of the market size owing to the well-established healthcare sector. Also, high per capita healthcare expenditures play a vital role in the market growth.

Whereas, the Asia Pacific region is expected to grow rapidly due to the emerging economies such as China and India.

In Gulf nations, particularly, Saudi Arabia and UAE drive the Middle Eastern & African market. The African region is estimated to witness moderate growth owing to poor economic & political conditions and inadequate healthcare facilities.

Key Players

Some of the market leaders profiled in the report are Abbott Laboratories, Allergan Plc., AstraZeneca, Eisai Co., Ltd., Endo International Plc., GlaxoSmithKline Plc., Impax Laboratories, Eli Lily and Company, Johnson & Johnson, and Merck & Co.

Research Methodology

The research report – Global Hemiplegic Migraine Market by Market Research Future comprises an in-depth primary research and the detailed analysis of qualitative as well as quantitative aspects of various industry experts. The detailed market analysis gives a clear picture of the current market scenarios including past and future market size in terms of value as well as volume alongside the technological advancement, macroeconomy, and governing factors of the market. The report provides detailed information and strategies of topnotch players in the market while providing a broad study of the market and its various segments in the outlined regions.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/hemiplegic-migraine-market-6713

Nuclear Medicine Market: Recent Industry Trends and Projected Industry Growth, 2020– 2023

 Market Research Future (MRFR)’s report highlights that the global nuclear medicine market is likely to strike a CAGR of 6.2% during the forecast period 2018 to 2023. The valuation of the market is expected to witness a growth of USD 5.430 Bn by the end of 2023. The growth of the market is dictated by increasing incidences of target conditions such as Cardiovascular Diseases (CVD) and cancer. Furthermore, the exponentially growing geriatric population is poised to add to the patient pool. The rising inclination towards the use of radiopharmaceuticals for the treatment of geriatric population is prognosticated to generate significant demand for nuclear medicines in the foreseeable future.

The market looks lucrative and is expanding at a significant pace. It is anticipated to witness constant growth over the next couple of years owing to increasing applications, discoveries, etc. Nevertheless, the expensiveness of the radiopharmaceuticals and side effects related to radiation exposure remain impediments to the market proliferation.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/6674

Report Coverage:

The report covers an in-depth study of the historical trends, current market status, forecast, and key players’ market share analysis. It also encompasses market factor analysis which includes supply chain analysis and Porter’s five forces analysis. The market is analyzed in detail by region as well as segmentation, and, a country-level analysis for each segment is also available in the report.

Report Overview:

This MRFR’s report offers a detailed five-year forecast (2018 to 2023) for the global nuclear medicine market. It reflects a revenue analysis of the different product types, including diagnostic nuclear medicine and therapeutic radiopharmaceuticals. The major applications discussed in the study encompasses diagnostic applications and therapeutic applications. The report also presents a detailed analysis of the end-users such as hospitals & diagnostic centers, research institutes, and others. A regional assessment of the market is published in the report for enhanced lucidity, which covers Americas, Europe, Asia Pacific, and the Middle East & Africa.

Companies Covered:

Some of the key players operating in the market are Cardinal Health, GE Healthcare, Bayer, Bracco Imaging, Curium, Lantheus Medical Imaging, Nordion Inc., Advanced Accelerators Applications, Mallinckrodt Pharmaceuticals, Jubliant Lifesciences, and Medtronic plc.

Research Methodology:

MRFR strives to leverage its industry expertise for offering insightful conclusions into the market that reflects the latest trends and foresight. Analytical algorithms are utilized for assessing and challenging the data curated through extensive primary and secondary research. The credible sources referred for data collection include interviews, SEC filings, whitepaper references, paid database services, etc. A multi-layer verification process authenticates the premium quality and reliability of the statistical observations offered in the report. Additionally, top-down and bottom-up approaches are employed for re-validating the accuracy of the quantitative assessment of the market.

Market Segmentation

MRFR has conducted a detailed study of the various parts of the nuclear medicine market which has been segmented on the basis of product type, application, end-user, and region. By product types, the nuclear medicine market has been segmented into diagnostic nuclear medicine and therapeutic radiopharmaceuticals. At present, the diagnostic nuclear medicine segment has attained a leadership position. However, the therapeutic radiopharmaceuticals segment is the fastest growing segment during the forecast period. The diagnostic nuclear medicine segment is segmented further into SPECT radiopharmaceuticals, and PET radiopharmaceuticals. Meanwhile, the therapeutic radiopharmaceuticals segment is sub-segmented into alpha emitters, beta emitters, and brachytherapy isotopes.

Applications of nuclear medicine are segmented into diagnostic applications and therapeutic applications. Diagnostic applications is a major segment which is sub-segmented into SPECT applications and PET applications. Meanwhile, the therapeutic applications segment is growing at the fastest pace.

End-users have been segmented into hospitals & diagnostic centers, research institutes, and others. Research institutes display the highest potential for growth over the forecast period, while hospitals & diagnostics centers have been identified as the most significant segment in terms of market share.

All sub-segments have been segmented further and included in the report.

Regional Analysis

The Americas due to the presence of North America has established itself as a market leader. The presence of several important market players combined with the high prevalence of cancer and other chronic diseases has influenced the growth of the Americas nuclear market. The region, particularly countries such as U.S & Canada have well-developed healthcare sectors which receive high investments. Moreover, the region has a high geriatric patient population which is expanding rapidly and is growing increasingly aware regarding advanced therapies.

Browse More Details of the Report @  https://www.marketresearchfuture.com/reports/nuclear-medicine-market-6674

Global Medical Device Security Market to Witness Steady Growth through 2023

 Market Overview

Market Research Future (MRFR)’s report reveals that the global medical device security market is set to expand at a CAGR of 8.8% during the forecast period 2018 to 2023. The valuation of the global market is estimated to witness a growth of USD 221 Mn over the review period. The developments in the healthcare sector have catalyzed the deployment of medical facilities systems. These devices are prone to hacking and pose a threat to the critical data related to healthcare centers and the privacy of the patients. Additionally, the rising cases of cyber-attacks have further intensified the security concern in the recent times. This trend is expected to create demand for medical device security solutions over the next couple of years.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6650

Rapid adoption of connected medical devices in the healthcare sector of developed and developing regions has increased the concerns regarding theft of personal medical data. Rise in incidences of cybercrime and misuse of personal data is inducing high demand for advanced medical device security modules, leading to the significant expansion of the global medical device security market. However, low penetration of technologically advanced medical devices, lack of awareness regarding the availability of advanced healthcare data security solutions and low healthcare budgets are likely to act as restraints on the expansion of the global medical device security market during the forecast period.

Market Segmentation:

The Global Medical Device Security Market has been segmented on the basis of component, type and end user. Based on component, the medical device security market has been segmented into solutions and services. The solutions segment has been sub-segmented into identity & access management solutions, antivirus/ antimalware solutions, encryption solutions, data loss prevention solutions, risk & compliance management, intrusion detection system/ intrusion prevention systems, disaster recovery solutions, distributed denial of service solutions and others. The services segment has been sub-segmented into professional services and managed security services. The professional services sub-segment includes consulting services, training & education, support & maintenance and design & integration. The solutions segment commands for the major share in the global medical device security market.

Based on type, the medical device security market has been segmented into network security, endpoint security, application security, cloud security and others. The endpoint security segment commands for the lion’s share in the global medical device security market. Based on end user, the medical device security market has been segmented into healthcare providers, medical device manufacturers and healthcare players. the healthcare providers segment commands for a dominant share in the global medical device security market.

Regional Analysis:

Geographically, the global medical device security market has been segmented into four major regions such as Europe, Americas, Asia Pacific and the Middle East and Africa. The Americas command for the major share in the global medical device security market owing to the presence of large number of players that are providing healthcare industry with advanced security solutions, rapid adoption of internet of things and higher threat of cyber-attacks in this region. The Europe region is projecting noteworthy growth in the global medical device security market owing to the increased incidences of cybercrime, rise in utilization of advanced connected medical devices and increased research and development expenditure for introducing highly effective security solutions in the healthcare sector in this region.

The Asia Pacific region is projecting significant expansion at the fastest growth rate in the global medical device security market owing to the increasing usage of connected medical devices that are operating with the help of healthcare IoT and rise in concern regarding data security in the healthcare sector of developing economies in this region. The Middle East and Africa region is expanding at a slow growth rate in the global medical device security market owing to the low penetration of advanced technology in the healthcare sector of the underdeveloped areas of this region.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/medical-device-security-market-6650 

Bowel Management Systems Market: Recent Industry Trends and Projected Industry Growth, 2020– 2023

 Rapid change in lifestyles and unhealthy dietary habits is leading to the rise in intestinal issues such as fecal incontinence and constipation among adults. With advancement in healthcare technology and development of various medical devices, these health issues are being managed with the help of bowel management systems.

Market Research Future (MRFR) has published a report asserting that the global bowel management systems market is marked to expand steadily at a CAGR of 4.1% during the forecast period of 2017-2023 and reach the valuation of 2.188 Bn by the end of 2023 from 1.72 Bn in 2017.
Global rise in geriatric population and dietary imbalance caused due to consumption of unhealthy food are majorly propelling the growth of the global bowel management systems market. However, concerns regarding the discomfort associated with the use of bowel management devices and inclination towards adoption of non-invasive treatments are likely to restrain the growth of the global bowel management systems market during the forecast period.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6649

Companies Covered

The leading players operating in the global bowel management systems market are Coloplast (Denmark), Medtronic (Ireland), 3M (the U.S.), B. Braun (Germany), C.R. Bard (the U.S.), Consure Medical (India), Cogentix Medical (the U.S.), Aquaflush Medical Limited (the U.K.), Axonics Modulation Technologies (the U.S.), ConvaTec (the U.K.), Hollister (the U.S.), MBH-International A/S (Denmark), Mederi Therapeutics Inc. (the U.S.), Welland Medical limited (the U.K.), and Wellspect HealthCare (Sweden).

Market Segmental Analysis

For scope of the report, MRFR offers a comprehensive segmental analysis of the global bowel management systems market

By Product

• Irrigation Systems 
• Colostomy Bags
• Nerve Modulation Devices (NMD)
• Other Products and Accessories

By Patient Type

• Adult Patients
• Pediatric Patients

By End User

• Home Care
• Hospitals & Ambulatory Surgery Centers

By Region

• Americas
• Europe
• Asia-Pacific
• Middle East and Africa

Report Overview

The MRFR’s market research report offers an unbiased and comprehensive assessment of key market dynamics in the global bowel management systems market. It includes discussion on current and historical market trends, challenges and growth opportunities backed by factful feedbacks. The primary types of products that are covered in the report are irrigation systems, colostomy bags, nerve modulation devices (NMD) and other products and accessories. The types of patients covered in the report are adult patients and pediatric patients. For opportunity analysis, the major end-users covered in the report are home care and hospitals and ambulatory surgery centers. All the sub-markets included in the report are profiled under four major regions such as Europe, Asia Pacific, Americas and the Middle East and Africa, with respective country-level analysis.

Research Methodology

Market Research Future (MRFR) leverages its comprehensive and iterative research methodology for the deliverance of highly accurate market insights. The primary and secondary research processes are utilized for conducting qualitative and quantitative analysis of current and historical market dynamics, consumer landscape, competitive landscape, market growth opportunities and challenges. Detailed surveys and first-hand interviews are conducted with the key opinion makers across the value chain for the collection of primary data. Secondary research processes are utilized for primary data validation through inputs from SEC filings, white paper references, paid databases, research publications and other credible sources available in public domain. The data triangulation techniques and top-down and bottom-up approaches are utilized to ensure accuracy and objectivity of the research findings.

Browse More Details of the Report @  https://www.marketresearchfuture.com/reports/bowel-management-systems-market-6649

Drug Discovery Informatics Market Growth Insight Analysis 2020-2023

 The global drug discovery informatics market held a market value of USD 1,680.6 million in 2017 and is projected to grow at a CAGR of 11.5% over the forecast period. Drug discovery and development is an extremely complex process requiring the generation of very large amounts of information data and. As the pharmaceutical and biotechnology industry is on the rise, information technology is supporting the drug discovery process to improve research productivity and success rates. Patent expiry of blockbuster drugs, an over-reliance on high throughput discovery strategies, and ongoing industry consolidation through mergers and acquisitions (M&A) are fueling the demand for drug discovery informatics. Few of the market growth factors include a worldwide rising focus on drug discovery, growing need to control drug discovery and development costs, rising research and development (R&D) expenditure, and increasing burden of chronic diseases. For instance, according to the Association of the British Pharmaceutical Industry (ABPI), the global pharmaceutical industry invested more than USD 1.36 trillion in R&D from 2007 to 2016, and it is projected to an annual investment of USD 181 billion by 2022. In contrast, high pricing and setup cost of informatics software is anticipated to limit the market growth during the forecast period.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/7831 

Introduction of in-silico tools that facilitate computation with varied workflows that are in sync with the rate of modern medicinal chemistry is one of the key trends augmenting market growth. It involves different steps and procedures which depend on in-silico tools for reducing the complexity of the process. In-silico tools include modeling tools for the determination of 3D structures of ligand and protein-absorption, distribution, metabolism, excretion, and toxicity (ADMET) assessment-affinity estimation in docking and drug-ligand interaction for pharmacological profiling.

Regional Analysis

The global drug discovery informatics market has been segmented by region into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. On the basis of region, the Americas is expected to hold higher market share over the forecast period pertaining to the presence of market value contributors, burgeoning pharmaceutical and biotechnology vertical, and rising prevalence of chronic diseases in the US and Canada. For instance, as per statistics published by the Center for Disease Control and Prevention (CDC), about 610,000 people die due to heart disease in the US every year (one in every four deaths).

Europe would follow the Americas in terms of value in the drug discovery informatics market owing to a surge in the clinical discovery ventures coupled with various activities conducted by research institutes, universities, and centers. The federal government acts as a regulator and also insures some public employees in Germany. Around 16 states in this county maintain public hospitals. The German government also proposes many healthcare programs to make citizens aware of the fatal disease.

Asia-Pacific would represent the fastest market growth during the forecast period owing to growing geriatric population coupled with rising prevalence of chronic diseases, increasing awareness and high adoption of drug discovery informatics, and surging number of clinical trials studies in the region.

The Middle East & Africa has the least share of the global drug discovery informatics market. In addition, the major market share of the region would be held by the Middle Eastern region due to developing healthcare system and medical infrastructure in the Arab countries.

Segmentation

The global drug discovery informatics market has been segmented into product, mode, service, end user, and region.

By product, the market has been segmented into discovery informatics and development informatics.

On the basis of mode, the market has been divided into in-house informatics and outsourced informatics. 

By service, the market has been classified into sequencing and target data analysis, docking, molecular modeling, clinical trial data management, and others. The sequencing and target data analysis segment is expected to dominate the market over the forecast period due to rising application of informatics solutions in targeted analysis and a large amount of data generated during the drug discovery process.

Based on end user, the market has been categorized into pharmaceutical and biotechnology industries, contract research organizations (CROs), and others.

Key Players

Few of the foremost players in the global drug discovery informatics market are Thermo Fisher Scientific, Inc., PerkinElmer, Inc., Certara, L.P., Infosys Limited, Novo Informatics Pvt. Ltd., Collaborative Drug Discovery Inc., Selvita, Charles River Laboratories, Inc., International Business Machines Corporation, Jubilant Life Sciences Ltd., IO Informatics, Inc., GVK Biosciences Private Limited, and Dassault Systèmes.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/drug-discovery-informatics-market-7831